Cardiovascular Disease Treatment Articles & Analysis
31 news found
” “For almost thirty years, there has been no innovative treatment approved to address the high risk of kidney disease progression in adults with chronic kidney disease and type 1 diabetes. ...
ByBayer AG
Kerendia is now indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. ...
ByBayer AG
These patients are in need of treatment options that can both delay kidney disease progression and reduce the risk of cardiovascular events,” said Dr. ...
ByBayer AG
CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. ...
ByBayer AG
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, has initiated the first-ever prospective coronary intervention study consisting of all female patients – EMPOWER CAD – to determine whether the positive results from earlier coronary IVL studies with the Shockwave C2 ...
The Jon DeHaan Foundation is dedicated to supporting those working to advance cardiac medicine and provides grants and awards to individuals and companies who focus on innovative developments in cardiovascular medicine, including research, prevention, diagnosis, treatment, or rehabilitation. ...
Reflecting the positive data from the pivotal Phase III FIGARO-DKD study on the reduction of the risk of cardiovascular events, the U.S.-label update announced today reaffirms Kerendia as a fundamental pillar in the treatment algorithm to improve outcomes in patients with chronic kidney disease associated with type 2 ...
ByBayer AG
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in two upcoming virtual investor conferences: The 2022 Wells Fargo Healthcare Conference Fireside Chat on Thursday, September 8, 2022, at 9:10 a.m. ...
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in two upcoming virtual investor conferences: The 2022 Wells Fargo Healthcare Conference Fireside Chat on Thursday, September 8, 2022, at 9:45 a.m. ...
CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. ...
ByBayer AG
The Shockwave M5 and S4 IVL Catheters, which are used for the treatment of peripheral arterial calcification lesions, are approved in the United States, the European Union, and other select international jurisdictions and have been used to help treat more than 50,000 patients globally who suffer from peripheral arterial disease. The Shockwave C2 Coronary IVL ...
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with IVL led to excellent long-term outcomes out to two years with preservation of future treatment options ...
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today new data confirming excellent one-year outcomes with coronary IVL in both women and men. ...
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the global commercial availability of the Shockwave M5+ peripheral IVL catheter after receiving both CE Mark and U.S. ...
“We look forward to providing patients and physicians in Japan with a new treatment option to delay kidney disease progression and reduce the risk of cardiovascular events. ...
ByBayer AG
CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. ...
ByBayer AG
CAC is a recognized vital biomarker for detection of cardiovascular disease. Nanox.AI believes that early detection and subsequent treatment of cardiovascular disease has the potential to significantly decrease the morbidity and mortality of this highly prevalent condition. HealthCCSng can be incorporated into ...
These patients have a critical need for treatment options that can delay kidney disease progression and reduce the risk of cardiovascular events,” said Professor Peter Rossing, Head of Complications Research at the Steno Diabetes Center Copenhagen. ...
ByBayer AG
Robocath, a company that designs, develops and commercializes robotic solutions to treat cardiovascular diseases, and Rennes University Hospital, today announce the launch of a co-development research program using robotics to improve treatment for stroke victims. ...
ByRobocath
The initiation of the Phase III FIONA study (FInerenone for the treatment of children with chrOnic kidNey disease and proteinuriA) builds upon the robust Phase III results from the FIDELIO-DKD and FIGARO-DKD studies which evaluated the effects of finerenone versus placebo on top of standard of care across a broad range of disease severity, on ...
ByBayer AG